CCAR-168 is under clinical development by AbelZeta and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...

Zanubrutinib is under clinical development by BeiGene and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase II drugs for Lupus Nephritis have a 50% phase transition success ...

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

but it still has some tricks up its sleeve – it’s just become the first and only FDA-approved treatment for lupus nephritis. The US regulator has cleared both intravenous and subcutaneous ...

A new study explored the potential of IncRNA CASC2 and miR-155 levels as non-invasive diagnostic biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Previous studies have found ...

Kidney inflammation caused by SLE is referred to as lupus nephritis (LN), and it is estimated that between 40% and 50% of all SLE patients will develop LN that requires treatment over the course ...

Treatment of lupus nephritis Treatment can be divided into an initial phase where treatment is most intense and aimed at controlling disease activity by suppressing autoimmune inflammation ...

Nkarta focuses on autoimmune diseases, with $402.5M in cash. Read why NKTX stock, currently undervalued, offers multiple ...

Objectives To report the 10-year outcome of lupus nephritis (LN) treated with mycophenolate mofetil (MMF) or tacrolimus (TAC) induction in a randomised controlled trial. Methods Patients with active ...

A 14-year-old patient presented to the ED with a 12-month history of joint pains and a 2-month history of headaches and ...

Geode Capital Management LLC boosted its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 12.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,094 ...